Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of QLS5314 Monotherapy in Participants With Advanced Solid Tumors

NCT07915856 is registered in ClinicalTrials.gov with Shanghai Qilu Pharmaceutical Research and Development Center LTD as lead sponsor.

NCT NCT07915856 Not yet recruiting Phase 1 70 participants (estimated) Started 2027

Follow this trial by email Email me the PDF

Get the NCT07915856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started January 2027. Interventional study, Phase 1, 70 participants (estimated). Lead sponsor Shanghai Qilu Pharmaceutical Research and Development Center LTD. Primary measures: Safety and Tolerability: Incidence and Severity of Adverse Events; Incidence of Dose-Limiting Toxicities (DLTs) and 2 more.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of QLS5314 Monotherapy in Participants With Advanced Solid Tumors
Official title
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of QLS5314 Monotherapy in Participants With Advanced Solid Tumors
Lead sponsor
Shanghai Qilu Pharmaceutical Research and Development Center LTD
Phase
Phase 1
Overall status
Not yet recruiting
Start date
January 26, 2027
Completion date
October 26, 2029
Enrollment
70 (estimated)
Sites
Not reported

Conditions

As the registry lists them.

advanced solid tumors

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
No
Study type
Interventional
Lead sponsor
Shanghai Qilu Pharmaceutical Research and Development Center LTD

Arms

As registered; 1 arm.

Registered arms
Arm Type Interventions
QLS5314 Monotherapy Experimental QLS5314

Primary endpoints

Registered primary outcome measures; 4 primary.

Registered primary endpoints
Measure Time frame
Safety and Tolerability: Incidence and Severity of Adverse Events From informed consent through 30 days (±7 days) after the last dose; treatment for up to 2 years.
Show registry wording

Number and percentage of participants with adverse events (AEs), treatment-emergent AEs (TEAEs), treatment-related AEs (TRAEs) and serious AEs (SAEs), by severity graded according to NCI-CTCAE v6.0 and relationship to QLS5314.

Incidence of Dose-Limiting Toxicities (DLTs) Cycle 1 Days 1-21 following first administration of QLS5314.
Show registry wording

Number and percentage of participants with protocol-defined DLTs during the Phase 1a dose-escalation stage.

Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) From the first dose until completion of Phase Ia dose escalation, up to approximately 11 months.
Show registry wording

MTD established using protocol-defined dose-escalation rules, or MAD if an MTD is not established.

Recommended Phase 2 Dose (RP2D) From the first dose until determination of the RP2D, up to approximately 20 months.
Show registry wording

RP2D determined using cumulative safety, tolerability, pharmacokinetic, immunogenicity, pharmacodynamic, biomarker and preliminary efficacy data.

Lead sponsor's other trials

Shanghai Qilu Pharmaceutical Research and Development Center LTD, most recent start first.